関: essential thrombocythemia、hemorrhagic thrombocythemia、primary thrombocythemia

WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 本態性血小板血症の予後および治療 prognosis and treatment of essential thrombocythemia
2. 血小板増加症患者に対するアプローチ approach to the patient with thrombocytosis
3. 本態性血小板血症の診断および臨床症状 diagnosis and clinical manifestations of essential thrombocythemia
4. 成人における門脈血栓症の疫学および病因 epidemiology and pathogenesis of portal vein thrombosis in adults
5. 骨髄異形成症候群の臨床症状および診断 clinical manifestations and diagnosis of the myelodysplastic syndromes

Dysfunction of the PI3 kinase/Rap1/integrin αIIbβ3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia.

Moore SF, Hunter RW, Harper MT, Savage JS, Siddiq S, Westbury SK, Poole AW, Mumford AD, Hers I.SourceSchool of Physiology and Pharmacology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom;
Blood.Blood.2012 Dec 13. [Epub ahead of print]
Patients with myeloproliferative disorders (MPD) such as essential thrombocythemia (ET) have increased risk of thrombosis and bleeding, which are major sources of morbidity and mortality. Most MPD patients have a gain of function mutation in Janus kinase 2 (JAK2V617F), but little is known how JAK2V6
PMID 23243278

Milosevic JD, Kralovics R.SourceCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT25.3, 1090, Vienna, Austria.
International journal of hematology.Int J Hematol.2012 Dec 12. [Epub ahead of print]
The classical BCR-ABL negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are clonal hematopoietic disorders characterized by excessive production of terminally differentiated myeloid cells. In MPN patients, the disease can progress to
PMID 23233154

The Gain-of-Function JAK2 V617F Mutation Shifts the Phenotype of Essential Thrombocythemia and Chronic Idiopathic Myelofibrosis to More "Erythremic" and Less "Thrombocythemic" : A Molecular, Histologic, and Clinical Study

RUDZKI Zbigniew,SACHA Tomasz,STOJ Anastazja,CZEKALSKA Sylwia,WOJCIK Malgorzata,SKOTNICKI Aleksander B.,GRABOWSKA Barbara,ZDUNCZYK Andrzej,OKON Krzysztof,STACHURA Jerzy
International journal of hematology 86(2), 130-136, 2007-08-15
NAID 10019733903

鶴見茂治
Dokkyo journal of medical sciences 30(1), 119-124, 2003-03-25
… 骨髄増殖症候群(myeloproliferative disorder : MPD)には真性赤血球増加症(polycythemia vera: PV),本態性血小板血症(essential thrombocythemia : ET) ,原発性骨髄線維症(idiopathic myelofibro-sis : MF)が含まれ,骨髄系細胞の慢性的な増殖を主徴とするが,その発症や病期進展に関与する分子病態については未だ不明の点が多い.我々は,本邦のMPD64症例(PV15例,ET38例,MF11例;慢性期例計58例,白血病化例計6例)につき,造血器腫瘍で多く変異がみ …
NAID 80016063729